1. Ubiquitin ligase DTX3 empowers mutant p53 to promote ovarian cancer development
- Author
-
Xiang Zhou, Qian Hao, Shanshan Wang, Yajie Chen, Xiaohua Wu, Jiajia Li, and Hua Lu
- Subjects
0301 basic medicine ,Mutant ,Cancer ,Cell Biology ,Biology ,medicine.disease ,Biochemistry ,Ubiquitin ligase ,RING finger domain ,03 medical and health sciences ,Ovarian tumor ,030104 developmental biology ,0302 clinical medicine ,Ubiquitin ,030220 oncology & carcinogenesis ,Ovarian carcinoma ,medicine ,biology.protein ,Cancer research ,Ovarian cancer ,Molecular Biology ,Genetics (clinical) - Abstract
The deltex family protein DTX3 is believed to possess E3 ubiquitin ligase activity, as it contains a classic RING finger domain. However, its biological role and the underlying mechanism in cancer remain largely elusive. Here, we identified DTX3 as a novel mutant p53-interacting protein in ovarian carcinoma. Mechanistically, DTX3 mediated mutant p53 ubiquitination and stabilization by perturbing the MDM2-mutant p53 interaction, consequently leading to activation of diverse mutant p53 target genes. Importantly, a positive correlation between the expression of DTX3 and mutant p53 target genes was further validated in ovarian carcinomas. Ectopic DTX3 promoted, while depletion of DTX3 suppressed, ovarian cancer cell proliferation and invasion. Remarkably, the pro-tumorigenic effect of DTX3 is dependent on mutant p53, because ablation of mutant p53 significantly impaired DTX3-induced gene expression and ovarian cancer cell growth and propagation. Furthermore, DTX3 elevated the expression of mutant p53 target genes and boosted ovarian tumor growth in vivo. Finally, DTX3 was amplified and overexpressed in ovarian carcinomas, which is significantly associated with unfavorable prognosis. Altogether, our findings unveil the oncogenic role of DTX3 in ovarian cancer development by bolstering mutant p53 activity.
- Published
- 2022